Business Update Positive

2026-05-28 18:07

Zydus Lifesciences announced that its subsidiary, Zydus Therapeutics, received US FDA Priority Review for its New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC). The PDUFA target action date is November 27, 2026. Phase 3 EPICS-III trial results demonstrated saroglitazar met the primary endpoint with 56.7% of patients achieving biochemical response versus 9.8% on placebo, and reduced ALP by 33.5%. If approved, Zydus plans a US launch in Q4 FY27.

Ownership Positive

2026-05-27 18:17

Zydus Lifesciences Limited announced an addendum to its share buyback public announcement. The buyback price has been increased from INR 1,150 to INR 1,260 per equity share. Concurrently, the maximum number of shares to be bought back has been reduced from 95,65,217 to 87,30,158 shares, representing up to 0.87% of the total paid-up capital. These changes were approved by the Buyback Committee on May 27, 2026.

Business Update Positive

2026-05-27 17:28

Zydus Lifesciences Limited's wholly owned subsidiary, Zydus Therapeutics, announced that the US FDA granted Priority Review to the New Drug Application (NDA) for saroglitazar. The proposed indication is for the treatment of Primary Biliary Cholangitis (PBC). The US FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 27, 2026.

Ownership Neutral

2026-05-26 15:30

Zydus Lifesciences Limited disclosed that Mr. Samar Babubhai Patel, a member of the Promoter Group, received 10,000 equity shares via transmission from Late Jasodaben Babubhai Patel, also a Promoter Group member. This off-market acquisition occurred on May 22, 2026, and was intimated to the company on May 25, 2026, as per SEBI PIT Regulations, 2015.

Business Update Positive

2026-05-24 21:39

Zydus Lifesciences' management reported a strong FY26 with healthy double-digit growth and record operating profitability, driven by robust performance across all segments and strategic acquisitions. For FY27, the company guides for high teens consolidated revenue growth, with North America expecting single-digit growth and India's branded formulations outperforming the market by 200-400 basis points. International markets are projected to maintain strong double-digit growth. EBITDA margins are guided to be in excess of 24% for FY27, a moderation from FY26 due to competition and commercialization expenses for Saro. R&D expenses are expected to be around 8% of FY27 revenue, with Capex projected at ₹1,500 crore. The Medical Devices and acquired manufacturing facilities are long-term growth drivers, expected to scale up in 2-4 years, while the specialty business is anticipated to see stronger momentum from FY28. The company aims to keep net debt to EBITDA comfortably below one-time.

Business Update Neutral

2026-05-23 15:31

Zydus Lifesciences Limited announced its participation in the Bank of America India Conference in Mumbai on June 2, 2026.

Routine Neutral

2026-05-21 13:12

New Filing detected. See link for details.

Business Update Neutral

2026-05-21 11:38

Zydus Lifesciences Limited will participate in the 360 ONE Capital (B&K) 16th Annual Investor Conference - TRINITY INDIA 2026 on May 27, 2026.

Business Update Positive

2026-05-20 12:52

Zydus Lifesciences Limited and its subsidiaries have completed the subscription of equity shares of Torrent Urja 25 Private Limited. On May 19, 2026, the company invested the remaining Rs. 90.18 million for 90,17,848 equity shares (Tranche 2, 3, and 4). This follows an earlier investment of Rs. 38.65 million for Tranche 1. The total investment represents 22.06% of Torrent Urja 25's paid-up share capital, aligning with Zydus's ESG principles and carbon neutrality goals.

Business Update Positive

2026-05-20 12:29

Zydus Lifesciences Limited and its subsidiaries have completed the subscription of equity shares in Torrent Urja 25 Private Limited. On May 19, 2026, the company invested an additional ₹90.18 million for 9,017,848 equity shares under Tranches 2, 3, and 4, representing 22.06% of Torrent Urja 25's paid-up share capital. This follows an earlier investment of ₹38.65 million for Tranche 1. The full subscription transaction has been consummated.

Governance Positive

2026-05-19 19:48

Zydus Lifesciences Limited's Board approved a share buyback on May 19, 2026. The company will buy back up to 95,65,217 equity shares (0.95% of total equity) at a price of INR 1,150 per share, amounting to an aggregate of INR 1,100 Crores. The buyback will be conducted via a tender offer, with May 29, 2026, as the record date. Funds will be from securities premium and free reserves, without using borrowed funds.

Business Update Neutral

2026-05-19 19:39

Zydus Lifesciences Limited informed about the availability of the audio recording of its Investor Call, which discussed the audited financial results for the quarter/year ended March 31, 2026. The recording is accessible on the company's website.

Ownership Positive

2026-05-19 19:20

Zydus Lifesciences Limited announced on May 19, 2026, that its Promoter Group and persons in control intend to participate in the previously approved share buyback. The buyback involves repurchasing up to 95,65,217 equity shares (0.95% of total) at a price of INR 1,150 per share, amounting to an aggregate of INR 1,100 Crores, via a tender offer route.

Financials Positive

2026-05-19 14:26

Zydus Lifesciences' Board approved a share buyback of up to 95,65,217 equity shares (0.95% of paid-up capital) at a price of INR 1,150/- per share, totaling INR 1,100 Crores. The buyback will be conducted via a tender offer, with May 29, 2026, set as the record date.

Financials Positive

2026-05-19 14:25

Zydus Lifesciences Limited's Board of Directors, at their meeting on May 19, 2026, approved a final dividend of Re. 1/- per equity share (100%) for the financial year ended March 31, 2026. The 31st Annual General Meeting will be held on August 11, 2026, where the dividend will be subject to shareholder approval. The record date for the dividend is July 24, 2026, with payment expected around August 14, 2026.

Financials Positive

2026-05-19 14:23

Consolidated Revenue ₹7,587 Cr vs ₹6,528 Cr (▲16.2% YoY), EBITDA ₹2,554 Cr vs ₹2,126 Cr (▲20.2% YoY), PAT ₹1,593 Cr vs ₹1,391 Cr (▲14.6% YoY). EBITDA Margin 33.7% vs 32.6% (▲110bps). The Board also recommended a 100% dividend and approved an equity share buyback.

Governance Positive

2026-05-19 14:16

Zydus Lifesciences Limited announced the re-appointment of Dr. Sharvil P. Patel as Managing Director for a further five years, effective April 1, 2027. Additionally, Mr. Kulin S. Lalbhai has been appointed as an Additional and Independent Director for five years, effective May 19, 2026. Both appointments are subject to shareholder approval at the upcoming Annual General Meeting.

Financials Positive

2026-05-19 14:15

Zydus Lifesciences Limited's Board approved a share buyback for up to 95,65,217 equity shares, representing 0.95% of the total paid-up capital. The buyback price is set at INR 1,150/- per share, amounting to an aggregate maximum of INR 1,100 Crores. The buyback will be conducted via a tender offer, with May 29, 2026, as the record date for determining eligible shareholders.

Financials Negative

2026-05-19 14:13

Consolidated Revenue ₹3,947.3Cr vs ₹5,767.8Cr (▼31.58% YoY), EBITDA ₹1,928.5Cr vs ₹3,577.7Cr (▼46.10% YoY), PAT ₹1,732.9Cr vs ₹2,815.8Cr (▼38.46% YoY). EBITDA Margin 48.86% vs 62.03% (▼1317bps). The Board also recommended a final dividend of Re. 1/- per equity share.

Financials Positive

2026-05-19 14:10

Zydus Lifesciences Limited reported consolidated financial results for the quarter ended March 31, 2026. Consolidated Revenue ₹7,587Cr vs ₹6,528Cr (▲16.22% YoY), EBITDA ₹2,157Cr vs ₹1,906Cr (▲13.17% YoY), PAT ₹1,273Cr vs ₹1,171Cr (▲8.68% YoY). EBITDA Margin 28.43% vs 29.20% (▼77bps). The Board also recommended a final dividend of Re. 1/- (@100%) per equity share of Re. 1/- each.

Business Update Positive

2026-05-13 21:02

Zydus Lifesciences Limited's subsidiary, Zydus Worldwide DMCC, will acquire Assertio Holdings, Inc. for approximately USD 166.4 million in cash. Assertio is a U.S. specialty oncology pharmaceutical company focused on supportive-care therapies, including ROLVEDON®. This strategic acquisition aims to establish an immediate U.S. specialty oncology commercial footprint for Zydus and expand its oncology portfolio. Assertio's turnover was USD 68.23 million in CY2025. The transaction is expected to close in FY 2026-27.

Business Update Negative

2026-05-13 17:23

CRITICAL RED FLAG DETECTED

Zydus Lifesciences Limited's appeal against a GST demand of Rs. 1.71 million and a penalty of Rs. 10.12 million pertaining to the period from July 2017 to March 2021 was upheld by the Appellate Authority. The company intends to file a second appeal before the GSTAT and states there is no material financial impact on the Company.

Business Update Neutral

2026-05-13 11:14

Zydus Lifesciences Limited announced that its Q4 FY26 (January-March 2026) financial results will be declared on Tuesday, May 19, 2026. A post-results earnings call and Q&A session, hosted by Dr. Sharvil Patel (Managing Director), is scheduled for the same day at 4:00 p.m. IST. Details for pre-registration are provided, and the audio recording and transcript will be available on the company's website.

Governance Neutral

2026-05-13 10:15

Zydus Lifesciences Limited announced that Mr. Apurva S. Diwanji (DIN: 00032072) ceased to be a Director, including an Independent Director, of the company effective May 12, 2026. His cessation is consequent upon the completion of his tenure. The company expressed appreciation for his contributions during his time.

Business Update Neutral

2026-05-06 11:04

Zydus Lifesciences announced the conclusion of a USFDA GMP surveillance inspection at its Biologics Injectable plant in Ahmedabad, conducted from April 27 to May 5, 2026. The inspection closed with seven observations, and importantly, there were no data integrity related observations. The company stated it will work closely with the USFDA to address these observations expeditiously.

Business Update Neutral

2026-05-05 09:42

CRITICAL RED FLAG DETECTED

Zydus VTEC Limited, a wholly-owned subsidiary of Zydus Lifesciences, received a demand order from the Deputy Commissioner of CGST & Central Excise for a demand and penalty of Rs. 9.00 million each (totaling Rs. 18.00 million or ₹1.8 crore) for alleged inadmissible Input Tax Credit for the period September 2020 to March 2023. The company intends to appeal the order, believing it has strong merits, and states there will be no material financial impact.

Business Update Positive

2026-05-01 13:03

Zydus Lifesciences, through its indirect wholly-owned subsidiary Amplitude SAS, has acquired 100% share capital of FBC Medical, France, for Euro 700,000. The acquisition, completed on April 30, 2026, aims to internalize commercial capabilities currently outsourced to third-party sales agents, thereby eliminating ongoing commission and business-development fees and reducing long-term selling and distribution costs. FBC Medical, specializing in medical equipment distribution, reported a turnover of Euro 935,000 in FY2025.

Business Update Positive

2026-05-01 12:56

Zydus Lifesciences' indirect wholly-owned subsidiary, Amplitude SAS, has acquired 100% share capital of Aptitude Orthopedie, France, for Euro 360,000. The acquisition, completed on April 30, 2026, is strategic, aiming to internalize commercial capabilities currently outsourced to third-party sales agents. This move is expected to eliminate ongoing commission and business-development fees, thereby reducing long-term selling and distribution costs for medical equipment.

Business Update Neutral

2026-04-30 11:26

Zydus Lifesciences Limited announced the incorporation of Zara Merger SUB Inc., a wholly-owned pharmaceutical subsidiary in the United States of America, on April 24, 2026. The new entity, formed for internal group restructuring, currently has no turnover and was capitalized by a 100% cash subscription.

Business Update Positive

2026-04-25 12:51

Zydus Lifesciences received approval from DCGI to initiate Phase III clinical trials for Zintrodiazine, a novel anti-malarial candidate. This marks a critical milestone in the fight against drug-resistant malaria, demonstrating progress in their R&D pipeline.

Business Update Positive

2026-04-16 12:48

Zydus Lifesciences received the USFDA's Establishment Inspection Report (EIR) and approval letter for its new oncology injectable manufacturing facility in SEZ1, Ahmedabad. The approval is for a new isolator injectable line after an inspection from Nov 4-13, 2025.

Business Update Positive

2026-04-16 09:39

Zydus Lifesciences' subsidiary, GRPPL, received an appeal order on April 1, 2026, dropping the entire GST penalty of Rs. 1.66 million related to alleged excess Input Tax Credit availment. The company confirms no material financial impact.

Business Update Positive

2026-04-10 09:42

Zydus Lifesciences received an overall ESG rating of 68 from ESGRAIL, a SEBI registered rating provider, an improvement from last year's 66. The report was independently prepared based on public information.

Routine Neutral

2026-04-08 17:27

Zydus Lifesciences Limited submitted the Confirmation Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2026, confirming the dematerialization of equity shares and substitution of the depository as the registered owner.

Business Update Positive

2026-04-08 09:45

Zydus Lifesciences received final USFDA approval for Dapagliflozin Tablets (5 mg and 10 mg), a generic version of Farxiga®. The company is eligible for 180 days of shared generic exclusivity for the drug, which had annual US sales of USD 10.2 billion.

Business Update Positive

2026-04-06 18:09

Zydus Lifesciences Limited announced receiving a favourable order from the Adjudication Authority, GST Department, leading to the drop of a GST demand of Rs. 41.77 million for the financial year 2019-20.

Business Update Negative

2026-04-01 10:47

CRITICAL RED FLAG DETECTED

Zydus Lifesciences received a tax demand order for ₹14.20 million under the CGST/HGST Act for alleged inadmissible Input Tax Credit from FY 2019-20 to 2023-24. The company believes it has strong merits, intends to appeal, and states there is no material financial impact.

Governance Neutral

2026-03-31 16:33

Zydus Lifesciences announced that Mr. Mayank Satpal transitioned from Senior Management effective March 31, 2026, due to organizational realignment. He will continue to be part of the company's leadership team.

Governance Negative

2026-03-27 09:52

CRITICAL RED FLAG DETECTED

Zydus Lifesciences reported a violation of SEBI PIT Regulations by Mr. Debtaru Upadhyay (General Manager - Marketing), who inadvertently sold 10 equity shares (contra trade) on March 13, 2026, incurring a loss of Rs. 170. The company issued a warning letter.

Ownership Neutral

2026-03-26 19:39

Zydus Lifesciences announced the closure of its trading window from April 1, 2026, for Directors and Designated Persons. The window will reopen 48 hours after the declaration of audited financial results for the quarter/financial year ending March 31, 2026, in compliance with insider trading regulations.

Business Update Neutral

2026-03-25 16:19

CRITICAL RED FLAG DETECTED

Zydus Lifesciences received an order from Assistant Commissioner of State Tax, Gujarat, demanding Rs. 3.28 Cr for alleged inadmissible Input Tax Credit for FY 2019-20. The company intends to appeal, believes it has strong merits, and states there is no material financial impact.

Business Update Positive

2026-03-21 08:17

Zydus Lifesciences Limited announced on March 21, 2026, the launch of Semaglutide Injection in India. Available in an innovative, reusable multi-dose pen device under brands SEMAGLYN™, MASHEMA™, and ALTERME™, it targets Type 2 Diabetes Mellitus and Obesity, costing approximately Rs. 2,200 monthly.

Business Update Positive

2026-03-19 09:29

Zydus Lifesciences Limited launched Aerolife Mini™ on March 19, 2026, an innovative, foldable next-gen pMDI enhancer. India's first of its kind, it aims to simplify inhaler use for asthma and COPD patients, licensed from AeroDel Technology Innovations Pvt. Ltd.

Business Update Positive

2026-03-18 15:09

Zydus Lifesciences and Torrent Pharma signed a licensing agreement on March 18, 2026, to co-market an innovative Semaglutide Injection in India for type 2 diabetes and chronic weight management. Zydus will manufacture and supply, while Torrent Pharma pays an upfront licensing fee and co-markets.

Business Update Positive

2026-03-17 12:01

Zydus Lifesciences and Lupin have signed a licensing agreement for co-marketing innovative Semaglutide Injection in India. This partnership aims to expand access to advanced therapies for diabetes and weight management, with Lupin paying Zydus upfront licensing fees and milestone payments.

Business Update Positive

2026-03-16 20:15

Zydus Lifesciences' subsidiary, Sentynl Therapeutics, licensed Progerinin (SLC-D011) from PRG S&T for Hutchinson-Gilford Progeria Syndrome. This investigational orphan drug, currently in Phase 2A clinical trials, strengthens Sentynl's rare disease portfolio.

Business Update Positive

2026-03-14 13:40

Zydus Lifesciences announced on March 14, 2026, that its drug 'Desidustat', licensed to China Medical System Holdings, received approval from NMPA of China for treating renal anaemia in non-dialysis adult CKD patients. The drug showed positive Phase III trial results, opening access to a significant market.

Business Update Positive

2026-03-13 10:04

Zydus Lifesciences received final USFDA approval for Cevimeline Hydrochloride Capsules 30mg, indicated for dry mouth. The product had annual sales of USD 26.9 million, enabling Zydus to manufacture and market the drug.

Business Update Positive

2026-03-12 14:22

Zydus Lifesciences launched AI-powered Continuous Glucose Monitors, Diasens™ and GlucoLive™, expanding its companion diagnostics portfolio. These devices offer real-time glucose monitoring for diabetic, CKD, and post-transplant patients, partnered with Digicare Health Solutions for integration with GoodFlip™ app.

Business Update Positive

2026-02-28 11:15

Zydus Lifesciences Limited received final USFDA approvals on Feb 28, 2026, for Ivermectin Tablets USP, 3 mg (annual sales USD 14.8 mn) and Dapsone Tablets USP, 25 mg and 100 mg (annual sales USD 8.4 mn).

Business Update Positive

2026-02-27 14:51

Zydus Lifesciences announced on Feb 27, 2026, the successful clinical development of Pembrolizumab biosimilar FYB206. The pivotal study achieved bioequivalence with Keytruda®, marking a milestone towards USFDA filing and positioning Zydus for the North American immuno-oncology market.

Business Update Positive

2026-02-25 18:50

Zydus Lifesciences announced plans to launch an innovative Semaglutide Injection (GLP-1 therapy) in India on patent expiry. Branded SEMAGLYN™, MASHEMA™, and ALTERME™, it features an indigenous, patient-friendly, reusable pen to enhance access and affordability for diabetes and obesity treatment.

Business Update Positive

2026-02-19 20:42

Zydus Lifesciences announced the closure of a USFDA Pre-Approval Inspection (PAI) for its Injectable plant in Ahmedabad (Unit 9), conducted from Feb 16-19, 2026. The inspection concluded with NIL observations, indicating successful compliance.

Business Update Positive

2026-02-19 09:51

Zydus Lifesciences launched Anyra™, India's first indigenously developed biosimilar Aflibercept 2 mg, on February 19, 2026. It is indicated for advancing ophthalmic care, treating conditions like wet AMD, DME, and Retinal Vein Occlusion.

Business Update Positive

2026-02-18 18:09

Zydus Lifesciences received final USFDA approval for Bosentan tablets for oral suspension, 32 mg, indicated for Pulmonary Arterial Hypertension. The drug had annual sales of USD 9.3 million in the US (IQVIA MAT Dec 2025).

Business Update Positive

2026-02-18 09:29

Zydus Lifesciences Limited will participate in the IIFL 17th Entrepreneurial India Conference 2026 in Mumbai on February 26, 2026.

Business Update Positive

2026-02-17 10:18

Zydus Lifesciences Limited announced on February 17, 2026, the launch of PEPAIR™™, India's first affordable, drug-free, handheld Oscillating Positive Expiratory Pressure (OPEP) device for respiratory health. Priced at Rs. 990, it aims to clear congestion and improve breathing for patients with COPD, Asthma, and Bronchiectasis.

Financials Positive

2026-02-15 19:22

Consolidated Revenue ₹6,860Cr vs ₹5,277Cr (▲30% YoY), EBITDA ₹1,820Cr vs ₹1,390Cr (▲31% YoY), PAT ₹1,110Cr vs ₹1,018Cr (▲9% YoY). EBITDA Margin 26.5% vs 26.3% (▲20bps).

Business Update Positive

2026-02-14 10:10

Zydus Lifesciences received final USFDA approval for Ammonium Lactate Cream, 12%, indicated for dry skin conditions. The product had estimated annual sales of USD 15 million in the US as of December 2025.

Business Update Positive

2026-02-12 08:27

Zydus Lifesciences settled patent litigation with Astellas Pharma Inc. over Myrbetriq® (Mirabegron). Zydus will pay USD 120 million and a per-unit licensing fee until September 2027, enabling them to continue marketing its generic Mirabegron in the US.

Business Update Neutral

2026-02-10 17:49

The audio recording of the Investor Call discussing the unaudited financial results for the quarter/nine months ended December 31, 2025, is now available on the Company's website as per SEBI Listing Regulations.

Financials Positive

2026-02-09 13:33

Consolidated Revenue ₹6,864.5Cr vs ₹5,269.1Cr (▲30.3% YoY), EBITDA ₹1,816.4Cr vs ₹1,387.6Cr (▲30.9% YoY), PAT ₹1,110.9Cr vs ₹1,023.5Cr (▲8.5% YoY). EBITDA Margin 26.5% vs 26.3% (▲20bps).

Financials Positive

2026-02-09 13:28

Revenue ₹6,864.5Cr vs ₹5,269.1Cr (▲30% YoY), EBITDA ₹1,816.4Cr vs ₹1,387.7Cr (▲31% YoY), Adjusted Net Profit ₹1,110.9Cr (▲9% YoY). EBITDA Margin 26.5% vs 26.3% (▲20 bps). The company also received positive regulatory updates from USFDA.

Governance Neutral

2026-02-09 13:24

CRITICAL RED FLAG DETECTED

Zydus Lifesciences' Board commented on ₹11,800 penalties each from BSE and NSE for technical non-compliance with SEBI Regulation 29. The issue was delayed intimation of a November 6, 2025 Board meeting for fund-raising, deemed inadvertent due to a trading holiday. The company has paid the fines.

Financials Positive

2026-02-09 13:21

Consolidated Revenue ₹6,864.5Cr vs ₹5,269.1Cr (▲30.3% YoY), EBITDA ₹1,731.5Cr vs ₹1,387.6Cr (▲24.8% YoY), PAT ₹1,042.1Cr vs ₹1,023.8Cr (▲1.8% YoY). EBITDA Margin 25.2% vs 26.3% (▼110bps).

Business Update Positive

2026-02-06 12:18

Zydus Lifesciences announced USFDA Orphan Drug Designation (ODD) for Desidustat for Sickle Cell Disease treatment. This designation provides eligibility for development incentives and potential seven-year marketing exclusivity upon USFDA approval, addressing an urgent medical need.

Business Update Positive

2026-02-04 14:39

Zydus Lifesciences received tentative USFDA approval for Dapagliflozin Tablets (5 mg & 10 mg) for type 2 diabetes. The drug had annual US sales of USD 10,486.9 mn (IQVIA MAT Dec 2025), indicating significant market potential.

Business Update Neutral

2026-02-04 10:17

Zydus Lifesciences Limited will participate in the Nuvama 21st India Conference in Mumbai on February 11, 2026.

ZYDUSLIFE

Zydus Lifesciences Limited

Filing History

Unlock Full History